arrow
D

David Baxter

University of London
H指数:80
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme

脑膜炎球菌ACWY结合疫苗对青少年咽部运输的影响: 英国MenACWY计划对群体保护的证据

2022-12-0134
OA
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

BNT162b2和mRNA-1273新型冠状病毒肺炎疫苗在两剂ChAdOx1 nCoV-19或BNT162b2和第三剂BNT162b2 (cov-boost) 后作为第四剂加强剂的安全性,免疫原性和反应原性: 多中心,盲法,2期随机试验

2022-08-01114
OAAI
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial

在英国,在两剂ChAdOx1 nCov-19或BNT162b2之后,作为第三剂加强剂给予七种新型冠状病毒肺炎疫苗后的免疫原性持久性: cov-boost试验的三个月分析

2022-06-0147
OAAI
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results

英国侵袭性脑膜炎球菌疾病发病率高和低期间的脑膜炎球菌携带: UKMenCar1-4横断面调查结果的比较

2021-05-0129
OAAI
Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profiling (vol 36, pg 746, 2018)

用于定量miRNA谱分析的小rna-seq方法的综合多中心评估 (第36卷,746页,2018)

2018-10-014
OAAI